Windlas Biotech Limited (NSE:WINDLAS)

India flag India · Delayed Price · Currency is INR
730.10
-13.25 (-1.78%)
Mar 9, 2026, 10:08 AM IST
-17.45%
Market Cap 15.58B
Revenue (ttm) 8.68B
Net Income (ttm) 667.47M
Shares Out 20.96M
EPS (ttm) 31.44
PE Ratio 23.65
Forward PE n/a
Dividend 5.80 (0.78%)
Ex-Dividend Date Jul 21, 2025
Volume 6,183
Average Volume 32,860
Open 737.00
Previous Close 743.35
Day's Range 714.85 - 742.20
52-Week Range 730.10 - 1,140.00
Beta 0.20
RSI 36.32
Earnings Date May 21, 2026

About Windlas Biotech

Windlas Biotech Limited, a contract development and manufacturing organization, manufactures and trades in pharmaceutical products in India. The company offers contract manufacturing; customized formulations; contract research and manufacturing services; customized formulation; and regulatory services. It also manufactures tablets, capsules, oral solids, modified-release formulations, chewable and dispersible tablets, customized generics, and complex generics and multi-drug combinations, as well as injectables, including liquid vials, lyophiliz... [Read more]

Sector Healthcare
Founded 2001
Employees 1,346
Stock Exchange National Stock Exchange of India
Ticker Symbol WINDLAS
Full Company Profile

Financial Performance

In fiscal year 2025, Windlas Biotech's revenue was 7.60 billion, an increase of 20.43% compared to the previous year's 6.31 billion. Earnings were 609.94 million, an increase of 4.82%.

Financial Statements

News

There is no news available yet.